Trimel Pharmaceuticals Confirms Next FDA Meeting on TEFINA

TORONTO--(BUSINESS WIRE)--Trimel Pharmaceuticals Corporation (TSX:TRL) today reported that it has scheduled a consultation meeting with the U.S. Food and Drug Administration (FDA) to be held in August to discuss TEFINA™, a “use as required” nasal testosterone gel in development for female orgasmic disorder. Building on the FDA feedback received earlier this year, the objective will be to review and solicit comments on the draft protocol for a subsequent study in the TEFINA™ clinical program.

Help employers find you! Check out all the jobs and post your resume.